THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 98 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2019. The put-call ratio across all filers is 6.05 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,754,591 | -21.6% | 203,313 | -5.9% | 0.00% | – |
| Q2 2023 | $2,237,184 | -1.8% | 216,153 | +2.9% | 0.00% | – |
| Q1 2023 | $2,278,652 | -4.0% | 210,014 | -0.7% | 0.00% | -100.0% |
| Q4 2022 | $2,374,107 | +13.9% | 211,596 | +3.0% | 0.00% | 0.0% |
| Q3 2022 | $2,084,000 | +26.5% | 205,470 | +12.9% | 0.00% | – |
| Q2 2022 | $1,648,000 | -9.1% | 181,915 | -4.1% | 0.00% | – |
| Q1 2022 | $1,813,000 | -12.8% | 189,697 | +0.7% | 0.00% | – |
| Q4 2021 | $2,080,000 | +59.3% | 188,326 | +6.7% | 0.00% | – |
| Q3 2021 | $1,306,000 | -48.7% | 176,421 | +0.6% | 0.00% | – |
| Q2 2021 | $2,546,000 | -38.3% | 175,359 | -13.3% | 0.00% | -100.0% |
| Q1 2021 | $4,129,000 | +12.8% | 202,309 | -1.8% | 0.00% | 0.0% |
| Q4 2020 | $3,662,000 | +17.4% | 206,080 | -2.3% | 0.00% | 0.0% |
| Q3 2020 | $3,119,000 | -31.0% | 210,975 | -2.0% | 0.00% | 0.0% |
| Q2 2020 | $4,519,000 | -7.3% | 215,315 | +2.1% | 0.00% | -50.0% |
| Q1 2020 | $4,875,000 | -7.4% | 210,968 | +3.7% | 0.00% | +100.0% |
| Q4 2019 | $5,265,000 | +37.0% | 203,368 | +3.1% | 0.00% | 0.0% |
| Q3 2019 | $3,843,000 | +13.2% | 197,271 | -5.1% | 0.00% | 0.0% |
| Q2 2019 | $3,394,000 | -28.4% | 207,843 | -0.7% | 0.00% | 0.0% |
| Q1 2019 | $4,743,000 | -10.9% | 209,209 | +0.5% | 0.00% | -50.0% |
| Q4 2018 | $5,326,000 | -20.7% | 208,117 | +1.2% | 0.00% | 0.0% |
| Q3 2018 | $6,716,000 | +43.7% | 205,570 | -0.3% | 0.00% | +100.0% |
| Q2 2018 | $4,674,000 | -8.2% | 206,090 | -1.8% | 0.00% | 0.0% |
| Q1 2018 | $5,090,000 | -13.4% | 209,907 | -0.4% | 0.00% | -50.0% |
| Q4 2017 | $5,876,000 | -18.4% | 210,681 | +0.2% | 0.00% | 0.0% |
| Q3 2017 | $7,202,000 | -13.0% | 210,331 | +1.3% | 0.00% | 0.0% |
| Q2 2017 | $8,274,000 | +9.1% | 207,707 | +0.8% | 0.00% | 0.0% |
| Q1 2017 | $7,586,000 | +18.5% | 206,023 | +2.6% | 0.00% | 0.0% |
| Q4 2016 | $6,403,000 | -20.4% | 200,835 | -9.5% | 0.00% | 0.0% |
| Q3 2016 | $8,039,000 | +97.1% | 221,844 | +23.4% | 0.00% | +100.0% |
| Q2 2016 | $4,079,000 | +51.4% | 179,769 | +25.4% | 0.00% | 0.0% |
| Q1 2016 | $2,695,000 | +16.9% | 143,372 | +2.0% | 0.00% | 0.0% |
| Q4 2015 | $2,305,000 | +63.0% | 140,620 | +9.3% | 0.00% | – |
| Q3 2015 | $1,414,000 | -16.0% | 128,616 | -0.6% | 0.00% | – |
| Q2 2015 | $1,684,000 | -18.4% | 129,351 | +8.7% | 0.00% | -100.0% |
| Q1 2015 | $2,064,000 | +18.7% | 118,994 | +2.1% | 0.00% | – |
| Q4 2014 | $1,739,000 | -37.4% | 116,508 | -3.3% | 0.00% | -100.0% |
| Q3 2014 | $2,777,000 | -63.7% | 120,497 | -49.8% | 0.00% | 0.0% |
| Q2 2014 | $7,660,000 | – | 240,250 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Madison Avenue Partners, LP | 7,269,584 | $69,497,223,000 | 12.98% |
| Newtyn Management, LLC | 1,375,000 | $13,145,000 | 3.15% |
| Chescapmanager LLC | 1,166,574 | $11,152,000 | 1.51% |
| Baupost Group | 13,643,333 | $130,430,000 | 1.40% |
| Weiss Asset Management LP | 5,412,487 | $51,743,000 | 1.07% |
| CM Management, LLC | 120,000 | $1,147,000 | 0.96% |
| Orbimed Advisors | 3,254,713 | $31,115,000 | 0.50% |
| King Wealth Management Group | 122,000 | $1,166,000 | 0.23% |
| Woodline Partners LP | 1,326,653 | $12,683,000 | 0.21% |
| PDT Partners, LLC | 192,701 | $1,842,000 | 0.16% |